| Texto completo | |
| Autor(es): |
Marques, Bruno L.
;
Lirio, Pedro H. C.
;
Vicente, Maria A.
;
Unzueta-Larrinaga, Paula
;
Uriguen, Leyre
;
Campos, Alline C.
Número total de Autores: 6
|
| Tipo de documento: | Artigo Científico |
| Fonte: | PHARMACEUTICALS; v. 18, n. 12, p. 32-pg., 2025-11-28. |
| Resumo | |
Background and Objectives: Neuropsychiatric disorders pose a major global health challenge, marked by high prevalence, limited diagnostic precision, and suboptimal therapeutic outcomes. Current diagnoses remain primarily clinical, lacking objective biomarkers, while many patients experience poor remission rates and frequent relapse. The endocannabinoid system (ECS), a central regulator of synaptic plasticity, neuroinflammation, and stress responses, is increasingly implicated in depression, anxiety, schizophrenia, and neurodegenerative diseases. In parallel, extracellular vesicles (EVs) have emerged as critical mediators of intercellular communication and promising biomarker sources, as they reflect the physiological or pathological status of their cells of origin. This review examines the hypothesis that interactions between ECS signaling and EV-mediated communication form a convergent pathway shaping vulnerability and resilience in neuropsychiatric disorders, with potential implications for biomarker identification and therapeutic innovation. Methods: This hypothesis-driven review was developed using a narrative approach, focusing on the interface between cannabinoids and EVs in neuropsychiatric conditions. Relevant publications were identified through PubMed, Scopus, and Web of Science searches up to September 2025. Results: Emerging evidence indicates a bidirectional relationship between ECS activity and EV biology: endocannabinoids can be loaded into EVs to facilitate intercellular signaling, while phytocannabinoids such as THC and CBD can alter EV release and cargo composition. Conclusions: We propose a hypothesis-driven framework in which the possible interplay between cannabinoids and EVs may stimulate new research and support the development of biomarker-guided, personalized therapeutic strategies for neuropsychiatric disorders. (AU) | |
| Processo FAPESP: | 24/18340-7 - Vesiculas extracelulares derivadas de células infectadas por SARS-CoV2 induzem alterações neuroplasticas em culturas neuronio-gliais derivadas do neuroepitélio olfativo humano. |
| Beneficiário: | Bruno Lemes Marques |
| Modalidade de apoio: | Bolsas no Exterior - Estágio de Pesquisa - Doutorado |
| Processo FAPESP: | 23/05979-7 - O canabidiol atenua os efeitos cognitivos de longo prazo produzidos pela via de sinalização mediada por exossomos derivados de células neurais infectadas com SARS-CoV-2: padronização de um modelo cognitivo de COVID longa. |
| Beneficiário: | Bruno Lemes Marques |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 23/04619-7 - Endocanabinoidoma com ferramenta para descoberta de marcadores do desenvolvimento do eixo cérebro-intestino-microbiota nos primeiros 1000 dias de vida |
| Beneficiário: | Alline Cristina de Campos |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 23/11032-2 - Mecanismos farmacológicos e moleculares de uma nanoprobe fluorescente contendo canabidiol em modelos de transtornos de neurodesenvolvimento: implicações para os transtornos do espectro autista e esquizofrenia. |
| Beneficiário: | Pedro Henrique Cassaro Lirio |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |